The EPO published Roche's patent application EP3845540A1 for novel chemical intermediates useful in synthesizing benzoxazepin compounds. The patent lists six inventors and covers pharmaceutical compositions with applications in oncology (A61P 35/00, A61P 35/04) and general therapeutic indications (A61P 43/00). Designated states include all major EU economies (DE, FR, GB, IT, ES, NL, BE, PL, SE) plus Switzerland, Norway, and Turkey.

Pharmaceutical companies developing benzoxazepin-based therapeutics or generic equivalents should review this patent for freedom-to-operate implications. The patent provides protection for synthesis intermediates, which could affect supply chain decisions for active pharmaceutical ingredient manufacturing. Companies should conduct landscape analyses to identify potential licensing needs or design-around strategies.